

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 019934-000310US



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On October 29, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Rosa

RECEIVED

NOV 06 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas J. Schall, et al.

Application No.: 09/944,163

Filed: August 30, 2001

For: MODULATORS OF US 28

Examiner: Jiang, S. Anna

Art Unit: 1617

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Madam:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

09944163


11/04/2003 SSANDARRA 00000015 201430

01 FC:1806 180.00 DA

This IDS is being filed before the mailing date of the final Office Action or
Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please
deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:mrv



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/944,163
		Filing Date	August 30, 2001
		First Named Inventor	Schall, Thomas J.
		Art Unit	1617
		Examiner Name	Jiang, S. Anna
Sheet 1 of 3	Attorney Docket Number	019934-000310US	

RECEIVED
NOV 6 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1	US-3,432,301	03-11-1969	Rauhut et al.	
	2	US-4,444,778	04-24-1984	Coughlin	
	3	US-5,935,995	08-10-1999	Bosslet et al.	
	4	US-5,948,775	09-07-1999	Koko et al.	
	5	US-6,034,102	03-07-2000	Aiello	
	6	US-6,150,132	11-21-2000	Wells et al.	
	7	US-2002/0061599 A1	05-23-2002	Elling et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	8	WO	98/11073		03-19-1998	Pharmacia & Upjohn Company		<input type="checkbox"/>
	9	WO	00/55377	A1	09-21-2000	New York Blood Center, Inc.		<input type="checkbox"/>
	10	EP	0 795 334	A2	09-17-1997	Hoechst AG		<input type="checkbox"/>
	11	NL	64014808		07-19-1965	Kalle AG		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60066705 v1



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/944,163	
			Filing Date	August 30, 2001	
			First Named Inventor	Schall, Thomas J.	
			Art Unit	1617	
			Examiner Name	Jiang, S. Anna	
Sheet	2	of	3	Attorney Docket Number	019934-000310US


RECEIVED
NOV 0 2003
TECH CENTER 16002900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	BEISSER, Patrick S. et al.: "The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection"; <u>Journal of Virology</u> ; Mar. 1998; Vol. 72, No. 3; pp. 2352-2363; American Society for Microbiology	
	13	BEISSER, Patrick S. et al.: "Deletion of the R78 G protein-coupled receptor gene from rat cytomegalovirus results in an attenuated, syncytium-inducing mutant strain"; <u>Journal of Virology</u> ; Sept. 1999; Vol. 73, No. 9; pp. 7218-7230; American Society for Microbiology	
	14	BILLSTROM, Marcella A. et al.: "Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection"; <u>Journal of Virology</u> ; July 1998; Vol. 72, No. 7; pp. 5535-5544	
	15	BODAGHI, Bahram, et al.: "Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells"; <u>J. Exp. Med.</u> ; September 7, 1998; Vol. 188, No. 5; pp. 855-866	
	16	CASAROSA, Paola et al.: "Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor"; <u>Journal of Biological Chemistry</u> ; February 14, 2003; Vol. 278; No. 7; pp. 5172-5178	
	17	CHEE, M.S. et al: "Human cytomegalovirus encodes three G protein-coupled receptor homologues"; <u>Nature</u> ; April 19, 1990; Vol. 344; pp. 774-777	
	18	DAVIS-POYTNER, Nicholas J. and Helen E. FARRELL: "Masters of deception: A review of herpesvirus immune evasion strategies"; <u>Immunology and Cell Biology</u> ; 1996; No. 74; ppl. 513-522	
	19	DAVIS-POYTNER Nicholas J. et al.: "Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus"; <u>Journal of Virology</u> ; Feb. 1997; Vol. 71, No. 2; pp. 1521-1529; American Society for Microbiology	
	20	DEBNATH, Asim K. et al.: "Structure based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type I"; <u>J. Med Chem.</u> ; 1999; Vol. 42; pp. 3203-3209	
	21	FARRELL, H.E. et al.: "Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue <i>in vivo</i> "; <u>Nature</u> ; April 3, 1997; Vol. 386; pp. 510-514	
	22	FLEMING, Peter et al.: "The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity"; <u>Journal of Virology</u> ; Aug. 1999; Vol. 73, No. 8; pp. 6800-6809; American Society for Microbiology	
	23	GAO J.L. and P.M. MURPHY: "Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor"; <u>J. Biol. Chem.</u> ; Nov. 18, 1994; Vol. 269, No. 46; pp. 28539-42	
	24	GRUNDY, Jane E., et al.: "Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration"; <u>The Journal of Infectious Diseases</u> ; 1998; Vol. 177; pp. 1465-1474	
	25	JILEK, J. O. et al.: "8-Halogenderivate von 10-(4-Methypiperazino)-10,11-Dihydrobenzo(b,f)thiepin un verwante Substanzen"; <u>Coll. Czechoslov. Chem. Commun.</u> ; 1968; Vol. 33; No. 6; pp. 1831-1845	
	26	KITAGUCHI, Tetsuya et al.: "Characterization of liposomes carrying von Willebrand factor-binding domain of platelet glycoprotein Ib α : A potential substitute for platelet transfusion"; <u>Biological and Biochemical Research Communications</u> ; 1999; Vol. 261; pp. 784-789; Academic Press, Inc.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **3**

Complete if Known

Application Number	09/944,163
Filing Date	August 30, 2001
First Named Inventor	Schall, Thomas J.
Art Unit	1617
Examiner Name	Jiang, S. Anna
Attorney Docket Number	019934-000310US

RECEIVED
NOV 8 2003
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	27	KLEDAL, Thomas N. et al.: "A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus"; <u>Science</u> ; September 12, 1997; Vol. 277; pp. 1656-1659	
	28	KLEDAL, Thomas N., et al.: "Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28"; <u>FEBS Letters</u> ; 1998; Vol. 441; pp. 209-214	
	29	MAHALINGAM, Surendran and Gunasegaran KARUPIAH: "Chemokines and chemokine receptors in infectious diseases"; <u>Immunology and Cell Biology</u> ; 1999; No. 77; pp. 469-475	
	30	MARGUILES, Barry J. et al.: "Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles"; <u>Virology</u> ; 1996; Vol. 225 No. 0579; pp. 111-125; Academic Press, Inc.	
	31	MYUNG, Chang-Seon et al.: "Development of an assay for phospholipase C using column-reconstituted, extruded phospholipid vesicles"; <u>Analytical Biochemistry</u> ; 1999; Vol. 270; pp. 303-313; Academic Press, Inc.	
	32	PADIA, Janak K. et al.: "Novel nonpeptide CCK-B antagonists: Design and development of quinoxalone derivatives as potent, selective, and orally active CCK-B antagonists"; <u>J. Med. Chem.</u> ; 1998; Vol. 41; pp. 1042-1049; American Chemical Society	
	33	PADIA, Janak K. et al.: "Design and synthesis of novel nonpeptide CCK-B receptor antagonists"; <u>Bioorganic & Medical Chemistry Letters</u> ; 1997; Vol. 7, No. 7; pp. 805-810; Elsevier Science Ltd.	
	34	PENFOLD, Mark E. T. et al.: "Cytomegalovirus encodes a potent α chemokine"; <u>Proc. Natl. Acad. Sci. USA</u> ; Aug. 1999; Vol. 96; pp. 9839-9844	
	35	ROLLINS, Barrett J.: "Chemokines"; <u>Blood</u> ; Aug. 1, 1997; Vol. 9, No. 3; pp. 909-928; The American Society of Hematology	
	36	SALLUSTO, Federica et al.: "Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses"; <u>Immunology Today</u> ; Dec. 1998; Vol. 19, No. 12; pp. 568-574; Elsevier Science Ltd.	
	37	SAEDERUP, Noah et al.: "Cytomegalovirus-encoded β chemokine promotes monocyte-associated viremia in the host"; <u>Proc. Natl. Acad. Sci. USA</u> ; Sept. 1999; Vol. 96; pp. 10881-10886	
	38	WARD, Stephen G. et al.: "Chemokines and T lymphocytes: More than an attraction"; <u>Immunity</u> ; Jul. 1998; Vol. 9; pp. 1-11; Cell Press	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.